Assaying the Kinase Activity of LRRK2 in vitro

被引:3
|
作者
Lewis, Patrick A. [1 ]
机构
[1] UCL Inst Neurol, Dept Mol Neurosci, London, England
来源
基金
英国惠康基金;
关键词
Molecular Biology; Issue; 59; Kinase; LRRK2; Parkinson's disease;
D O I
10.3791/3495
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Leucine Rich Repeat Kinase 2 (LRRK2) is a 2527 amino acid member of the ROCO family of proteins, possessing a complex, multidomain structure including a GTPase domain (termed ROC, for Ras of Complex proteins) and a kinase domain(1). The discovery in 2004 of mutations in LRRK2 that cause Parkinson's disease (PD) resulted in LRRK2 being the focus of a huge volume of research into its normal function and how the protein goes awry in the disease state(2,3). Initial investigations into the function of LRRK2 focused on its enzymatic activities(4-6). Although a clear picture has yet to emerge of a consistent alteration in these due to mutations, data from a number of groups has highlighted the importance of the kinase activity of LRRK2 in cell death linked to mutations(7,8). Recent publications have reported inhibitors targeting the kinase activity of LRRK2, providing a key experimental tool(9-11). In light of these data, it is likely that the enzymatic properties of LRRK2 afford us an important window into the biology of this protein, although whether they are potential drug targets for Parkinson's is open to debate. A number of different approaches have been used to assay the kinase activity of LRRK2. Initially, assays were carried out using epitope tagged protein overexpressed in mammalian cell lines and immunoprecipitated, with the assays carried out using this protein immobilised on agarose beads(4,5,7). Subsequently, purified recombinant fragments of LRRK2 in solution have also been used, for example a GST tagged fragment purified from insect cells containing residues 970 to 2527 of LRRK2(12). Recently, Daniels et al. reported the isolation of full length LRRK2 in solution from human embryonic kidney cells, however this protein is not widely available(13). In contrast, the GST fusion truncated form of LRRK2 is commercially available (from Invitrogen, see table 1 for details), and provides a convenient tool for demonstrating an assay for LRRK2 kinase activity. Several different outputs for LRRK2 kinase activity have been reported. Autophosphorylation of LRRK2 itself, phosphorylation of Myelin Basic Protein (MBP) as a generic kinase substrate and phosphorylation of an artificial substrate - dubbed LRRKtide, based upon phosphorylation of threonine 558 in Moesin - have all been used, as have a series of putative physiological substrates including alpha-synuclein, Moesin and 4-EBP14-17. The status of these proteins as substrates for LRRK2 remains unclear, and as such the protocol described below will focus on using MBP as a generic substrate, noting the utility of this system to assay LRRK2 kinase activity directed against a range of potential substrates.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
    Greggio, Elisa
    Jain, Shushant
    Kingsbury, Ann
    Bandopadhyay, Rina
    Lewis, Patrick
    Kaganovich, Alice
    van der Brug, Marcel P.
    Beilina, Alexandra
    Blackinton, Jeff
    Thomas, Kelly Jean
    Ahmad, Rill
    Miller, David W.
    Kesavapany, Sashi
    Singleton, Andrew
    Lees, Andrew
    Harvey, Robert J.
    Harvey, Kirsten
    Cookson, Mark R.
    NEUROBIOLOGY OF DISEASE, 2006, 23 (02) : 329 - 341
  • [22] Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
    Lobbestael, E.
    Civiero, L.
    De Wit, T.
    Taymans, J. -M.
    Greggio, E.
    Baekelandt, V.
    SCIENTIFIC REPORTS, 2016, 6
  • [23] In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity
    Novello, Salvatore
    Mercatelli, Daniela
    Albanese, Federica
    Domenicale, Chiara
    Brugnoli, Alberto
    D'Aversa, Elisabetta
    Vantaggiato, Silvia
    Dovero, Sandra
    Murtaj, Valentina
    Presotto, Luca
    Borgatti, Monica
    Shimshek, Derya R.
    Bezard, Erwan
    Moresco, Rosa Maria
    Belloli, Sara
    Morari, Michele
    NEUROBIOLOGY OF DISEASE, 2022, 162
  • [24] Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease
    Greggio, Elisa
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1058 - 1062
  • [25] Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
    E. Lobbestael
    L. Civiero
    T. De Wit
    J.-M. Taymans
    E. Greggio
    V. Baekelandt
    Scientific Reports, 6
  • [26] How mutations in LRRK2 affect kinase activity, and why it matters
    Cookson, M. R.
    JOURNAL OF NEUROCHEMISTRY, 2008, 104 : 91 - 91
  • [27] Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on Dimerization
    Sen, Saurabh
    Webber, Philip J.
    West, Andrew B.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (52) : 36346 - 36356
  • [28] Phosphorylation of LRRK2: from kinase to substrate
    Lobbestael, Evy
    Baekelandt, Veerle
    Taymans, Jean-Marc
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1102 - 1110
  • [29] Exosome markers of LRRK2 kinase inhibition
    Wang, Shijie
    Kelly, Kaela
    Brotchie, Jonathan M.
    Koprich, James B.
    West, Andrew B.
    NPJ PARKINSONS DISEASE, 2020, 6 (01)
  • [30] LRRK2 kinase in Parkinson's disease
    Alessi, Dario R.
    Sammler, Esther
    SCIENCE, 2018, 360 (6384) : 36 - 37